Odyssey Therapeutics is attempting an IPO again after pulling its first attempt earlier, according to coverage that says the company submitted a second registration. The update signals continued capital-market ambition for the company and a willingness to re-engage despite prior market reception. For public-market biotech, IPO timing can heavily influence runway and trial financing strategies, especially for companies with clinical-stage assets that require steady cash infusions. Odyssey’s move suggests management views conditions as improving enough to pursue public funding. The practical read-through is capital access for near-term development milestones—an issue that can determine how quickly programs progress once clinical data are in hand.